Senescent cells under chronic stress rely on autophagy as a rationing system that fuels ATP production for SASP secretion while Bcl‑2 family proteins block apoptosis [1][2]. This siege metabolism lets them persist despite damage, and interventions that merely boost autophagy (e.g., rapamycin, intermittent fasting) may actually prolong survival by improving the efficiency of the rationing loop. We hypothesize that simultaneous blockade of Bcl‑2–mediated apoptosis inhibition and lysosomal autophagy will convert the siege from a survivable state into lethal energetic collapse, but only when the NRF2‑driven autophagy gate is low or inhibited.

NRF2 activates autophagy and concurrently suppresses senescence [4], creating a bifurcation where high NRF2 favors autophagy‑dependent survival and low NRF2 favors apoptosis. If NRF2 is high, senescent cells can maintain ATP through autophagy even when Bcl‑2 is inhibited, rendering the combination ineffective. Conversely, when NRF2 activity is reduced (by genetic knockdown or pharmacological inhibition with brusatol), autophagy becomes less capable of compensating for Bcl‑2 loss, leading to ATP depletion, loss of mitochondrial membrane potential, and caspase‑3 activation.

Testable prediction: In human diploid fibroblasts rendered senescent by irradiation, treatment with venetoclax (Bcl‑2 selective inhibitor) plus chloroquine (lysosomal autophagy inhibitor) will increase Annexin V/PI‑positive apoptotic cells and reduce SASP IL‑6 and IL‑8 secretion only in conditions where NRF2 is silenced (siRNA) or inhibited, compared with venetoclax alone or chloroquine alone. If NRF2 remains active, the combination will not produce a significant increase in apoptosis over venetoclax monotherapy.

Experimental outline:

1. Induce senescence in IMR‑90 cells (10 Gy IR). Verify SA‑β‑gal and p16^INK4a^ upregulation.
2. Transfect with NRF2‑targeting siRNA or treat with brusatol (NRF2 inhibitor); include non‑targeting siRNA and DMSO controls.
3. Treat groups for 48 h with: vehicle, venetoclax (100 nM), chloroquine (10 µM), venetoclax + chloroquine.
4. Measure:
   • Cell viability (CellTiter‑Glo).
   • Apoptosis (caspase‑3/7 activity, Annexin V flow).
   • Mitochondrial ATP levels (luminescent assay).
   • SASP cytokines (ELISA for IL‑6, IL‑8).
   • Autophagic flux (LC3‑II/I ratio with bafilomycin A1).
5. Statistical analysis via two‑way ANOVA (factors: NRF2 status, drug treatment).

Falsifiability: If NRF2‑high senescent cells show equal or greater apoptosis and SASP reduction with venetoclax + chloroquine compared to NRF2‑low cells, the hypothesis is falsified. Likewise, if chloroquine does not further reduce ATP or increase apoptosis beyond venetoclax alone irrespective of NRF2 level, the siege‑metabolism premise is unsupported.

Implications: This reframes senolytic design—not merely adding another hit but targeting the metabolic contingency that lets senescent cells endure Bcl‑2 inhibition. Success would justify prioritizing Bcl‑2 inhibitor combinations that also modulate NRF2 or autophagy flux in aging trials, providing a mechanistic edge over the broader but less selective D+Q regimen while remaining testable in near‑term human studies.